Voyager Therapeutics, Inc. (VYGR): Price and Financial Metrics


Voyager Therapeutics, Inc. (VYGR): $4.59

0.05 (+1.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VYGR POWR Grades


  • VYGR scores best on the Value dimension, with a Value rank ahead of 96.05% of US stocks.
  • VYGR's strongest trending metric is Growth; it's been moving down over the last 29.7142857142857 weeks.
  • VYGR's current lowest rank is in the Growth metric (where it is better than 1.07% of US stocks).

VYGR Stock Summary

  • With a price/earnings ratio of 4.35, Voyager Therapeutics Inc P/E ratio is greater than that of about merely 4.07% of stocks in our set with positive earnings.
  • For VYGR, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
  • Over the past twelve months, VYGR has reported earnings growth of -196.72%, putting it ahead of only 10.77% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Voyager Therapeutics Inc, a group of peers worth examining would be MTEM, ZYME, SGMO, DTIL, and CERC.
  • VYGR's SEC filings can be seen here. And to visit Voyager Therapeutics Inc's official web site, go to www.voyagertherapeutics.com.

VYGR Price Target

For more insight on analysts targets of VYGR, see our VYGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.61 Average Broker Recommendation 1.82 (Hold)

VYGR Stock Price Chart Interactive Chart >

Price chart for VYGR

VYGR Price/Volume Stats

Current price $4.59 52-week high $14.62
Prev. close $4.54 52-week low $3.89
Day low $4.46 Volume 260,503
Day high $4.72 Avg. volume 565,450
50-day MA $4.88 Dividend yield N/A
200-day MA $8.29 Market Cap 173.17M

Voyager Therapeutics, Inc. (VYGR) Company Bio


Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company was founded in 2013 and is based in Cambridge, Massachusetts.


VYGR Latest News Stream


Event/Time News Detail
Loading, please wait...

VYGR Latest Social Stream


Loading social stream, please wait...

View Full VYGR Social Stream

Latest VYGR News From Around the Web

Below are the latest news stories about Voyager Therapeutics Inc that investors may wish to consider to help them evaluate VYGR as an investment opportunity.

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the American Society of Gene and Cell Therapy. Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease. Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies. Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are f...

Yahoo | May 12, 2021

Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody

Findings to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic strategy for treating various tauopathies CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases today will present new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually May 11-14, 2021. “Tauopathies such as progressive supranuclear palsy, frontal temporal dementia, and Alzheimer’s dise...

Yahoo | May 12, 2021

10 Best Stocks for Beginners with Little Money

In this article we will take a look at the 10 best stocks for beginners with little money. You can skip our comprehensive analysis of these stocks and go directly to the 5 Best Stocks for Beginners with Little Money. There are many questions and uncertainties that cross the mind of an individual who wants […]

Yahoo | April 27, 2021

Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Yahoo | April 27, 2021

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

Voyager Therapeutics, Inc. (NASDAQ: VYGR ), uniQure N.V. (NASDAQ: QURE ), Axsome Therapeutics, Inc. (NASDAQ: AXSM ), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session. Voyager Gains On Lifting of Clinical Hold On Huntington's Disease Gene Therapy: Voyager, a gene therapy company developing treatments for severe neurological diseases, said the Food and Drug Administration has removed the clinical hold imposed on the company's investigational new drug application for VY-HTT01. VY-HTT01 is a gene therapy candidate that is being evaluated for the treatment of Huntington's disease. The FDA has communicated to the company that it can proceed with the planned Phase 1/2 study. The company said it ...

Benzinga | April 26, 2021

Read More 'VYGR' Stories Here

VYGR Price Returns

1-mo 0.66%
3-mo -36.43%
6-mo -46.63%
1-year -64.72%
3-year -75.53%
5-year -59.49%
YTD -35.80%
2020 -48.75%
2019 48.40%
2018 -43.37%
2017 30.30%
2016 -41.83%

Continue Researching VYGR

Here are a few links from around the web to help you further your research on Voyager Therapeutics Inc's stock as an investment opportunity:

Voyager Therapeutics Inc (VYGR) Stock Price | Nasdaq
Voyager Therapeutics Inc (VYGR) Stock Quote, History and News - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9414 seconds.